These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure. Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032 [TBL] [Abstract][Full Text] [Related]
12. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504 [TBL] [Abstract][Full Text] [Related]
13. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699 [TBL] [Abstract][Full Text] [Related]
14. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers. Schnell D; Burleigh K; Trick J; Seifert R J Pharmacol Exp Ther; 2010 Mar; 332(3):996-1005. PubMed ID: 19959746 [TBL] [Abstract][Full Text] [Related]
15. Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR studies. Lim HD; Istyastono EP; van de Stolpe A; Romeo G; Gobbi S; Schepers M; Lahaye R; Menge WM; Zuiderveld OP; Jongejan A; Smits RA; Bakker RA; Haaksma EE; Leurs R; de Esch IJ Bioorg Med Chem; 2009 Jun; 17(11):3987-94. PubMed ID: 19414267 [TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. Istyastono EP; Nijmeijer S; Lim HD; van de Stolpe A; Roumen L; Kooistra AJ; Vischer HF; de Esch IJ; Leurs R; de Graaf C J Med Chem; 2011 Dec; 54(23):8136-47. PubMed ID: 22003888 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands. Geyer R; Kaske M; Baumeister P; Buschauer A Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592 [TBL] [Abstract][Full Text] [Related]
18. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure. Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960 [TBL] [Abstract][Full Text] [Related]
19. Selective histamine H₃ and H₄ receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach. Coruzzi G; Adami M; Pozzoli C; de Esch IJ; Smits R; Leurs R Eur J Pharmacol; 2011 Nov; 669(1-3):121-7. PubMed ID: 21839070 [TBL] [Abstract][Full Text] [Related]
20. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor. Deml KF; Beermann S; Neumann D; Strasser A; Seifert R Mol Pharmacol; 2009 Nov; 76(5):1019-30. PubMed ID: 19720730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]